DEFEROXAMINE MESYLATE Drug Patent Profile
✉ Email this page to a colleague
When do Deferoxamine Mesylate patents expire, and when can generic versions of Deferoxamine Mesylate launch?
Deferoxamine Mesylate is a drug marketed by Dr Reddys, Fresenius Kabi Usa, Gland Pharma Ltd, Hospira, and West-ward Pharms Int. and is included in five NDAs.
The generic ingredient in DEFEROXAMINE MESYLATE is deferoxamine mesylate. There are seven drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the deferoxamine mesylate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Deferoxamine Mesylate
A generic version of DEFEROXAMINE MESYLATE was approved as deferoxamine mesylate by HOSPIRA on March 17th, 2004.
Summary for DEFEROXAMINE MESYLATE
US Patents: | 0 |
Applicants: | 5 |
NDAs: | 5 |
Finished Product Suppliers / Packagers: | 5 |
Raw Ingredient (Bulk) Api Vendors: | 82 |
Clinical Trials: | 6 |
Patent Applications: | 1,420 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for DEFEROXAMINE MESYLATE |
DailyMed Link: | DEFEROXAMINE MESYLATE at DailyMed |
Recent Clinical Trials for DEFEROXAMINE MESYLATE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Aditya S. Pandey, MD | Phase 2 |
Michigan Medicine PKUHSC Joint Institute for Translational & Clinical Research | Phase 2 |
The 263 Hospital of PLA | Phase 1/Phase 2 |
Pharmacology for DEFEROXAMINE MESYLATE
Drug Class | Iron Chelator |
Mechanism of Action | Iron Chelating Activity |